Lipigon Q3 2023: Stage set for Phase II - Redeye

Redeye comments on Lipigon's Q3 report 2023. The main event since our last comment is the application to start the phase II trial which was submitted in November. The company also reported a statistically significant reduction of ANGPTL4 of 29% in the phase I study.

Länk till analysen i sin helhet: https://www.redeye.se/research/962599/lipigon-q3-2023-stage-set-for-phase-ii?utm_source=finwire&utm_medium=RSS